ALK inhibitor

Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...


ALTA trial has evaluated 2 doses of the ALK inhibitor Brigatinib post-Crizotinib. Overall objective response rate ( ORR ) contains...


The FDA ( U.S. Food and Drug Administration ) has approved Xadago ( Safinamide ) tablets as an add-on treatment...


Phase 2 results for Ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of...


The European Commission ( EC ) has approved Alecensa ( Alectinib ), a second-generation ALK inhibitor, for the frontline treatment...


Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival...


The FDA ( Food and Drug Administration ) has found that type 2 diabetes medicines containing Saxagliptin and Alogliptin may...


Renal cell carcinoma ( RCC ) accounts for approximately 330,000 cases diagnosed each year and 140,000 deaths worldwide. Most cases are...


A promising approach to neurotherapeutics involves activating the nuclear-factor-E2-related factor 2 ( Nrf2 ) / antioxidant response element signaling, which...


The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...


A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening...


Data were reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer ( WCLC )...


FDA ( Food and Drug Administration ) has strengthened the warning for the type 2 diabetes medicine Canagliflozin ( Invokana,...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda...


The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias...


Alectinib ( Alecensa ) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase ( ALK...


Results from two pivotal studies ( NP28673 and NP28761 ) have showen Alectinib, an oral investigational anaplastic lymphoma kinase inhibitor...


Lung cancer is the number one cause of cancer mortality globally and has an estimated incidence of 1.3 million new...